The estimated Net Worth of Sean E Harper is at least $31.3 Milion dollars as of 16 July 2018. Sean Harper owns over 1,525 units of AMGEN stock worth over $18,505,938 and over the last 13 years Sean sold AMGN stock worth over $12,803,603.
Sign up
Sean Harper AMGN stock SEC Form 4 insiders trading
Sean has made over 16 trades of the AMGEN stock since 2012, according to the Form 4 filled with the SEC. Most recently Sean sold 1,525 units of AMGN stock worth $298,458 on 16 July 2018.
The largest trade Sean's ever made was exercising 39,900 units of AMGEN stock on 27 July 2012 worth over $2,730,357. On average, Sean trades about 2,712 units every 44 days since 2012. As of 16 July 2018 Sean still owns at least 56,082 units of AMGEN stock.
You can see the complete history of Sean Harper stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Sean Harper's mailing address?
Sean's mailing address filed with the SEC is ONE AMGEN CENTER DRIVE, , THOUSAND OAKS, CA, 91320-1799.
Insiders trading at AMGEN
Over the last 21 years, insiders at AMGEN have traded over $219,663,137 worth of AMGEN stock and bought 8,904 units worth $919,219 . The most active insiders traders include Robert Eckert, Kevin W Sharer oraz Ellen Jamison Kullman. On average, AMGEN executives and independent directors trade stock every 35 days with the average trade being worth of $8,732,261. The most recent stock trade was executed by Nancy A. Grygiel on 3 May 2024, trading 2,117 units of AMGN stock currently worth $662,812.
What does AMGEN do?
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the worlds largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.
What does AMGEN's logo look like?
Complete history of Sean Harper stock trades at AMGEN
AMGEN executives and stock owners
AMGEN executives and other stock owners filed with the SEC include:
-
Robert Bradway,
Chairman of the Board, President, Chief Executive Officer -
Jonathan Graham,
Senior Vice President, General Counsel, Secretary -
Murdo Gordon,
Executive Vice President of Global Commercial Operations -
David Reese,
Executive Vice President - Research and Development -
Robert A. Bradway,
Chairman, CEO & Pres -
Murdo Gordon,
Exec. VP of Global Commercial Operations -
Dr. David M. Reese M.D.,
Exec. VP of R&D -
Esteban Santos,
Exec. VP of Operations -
Peter H. Griffith,
Exec. VP & CFO -
Robert Eckert,
Lead Independent Director -
Gregory Garland,
Independent Director -
Ronald Sugar,
Independent Director -
Charles Holley,
Independent Director -
Wanda Austin,
Independent Director -
Brian Druker,
Independent Director -
Fred Hassan,
Independent Director -
Robert Williams,
Independent Director -
Tyler Jacks,
Independent Director -
Ellen Kullman,
Independent Director -
Amy Miles,
Independent Director -
Linda Louie,
Vice President - Finance, Chief Accounting Officer -
David Piacquad,
Senior Vice President - Business Development -
Lori Johnston,
Senior Vice President - Human Resources -
Cynthia Patton,
Senior Vice President, Chief Compliance Officer -
Esteban Santos,
Executive Vice President, Operations -
Peter Griffith,
Chief Financial Officer, Executive Vice President -
Nancy A. Grygiel,
Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer -
Jonathan P. Graham,
Exec. VP, Gen. Counsel & Sec. -
Arvind Sood,
VP of Investor Relations -
Mike Zahigian,
Sr. VP & Chief Information Officer -
Linda H. Louie,
VP of Fin. & Chief Accounting Officer -
Annette Louise Such,
CAO -
Frank Biondi,
Director -
Greg C. Garland,
Director -
Frank C Herringer,
Director -
David W Meline,
EVP & CFO -
Anthony C Hooper,
EVP, Global Commercial Ops. -
R Sanders Williams,
Director -
Rebecca M Henderson,
Director -
Judith C Pelham,
Director -
David Baltimore,
Director -
Sean E Harper,
EVP, Research & Development -
Carbonnel Francois De,
Director -
James E. Bradner,
EVP, R&D, & Chief Sci. Officer -
Nancy A. Grygiel,
SVP & CCO -
Thomas James Flanagan,
Sr VP & CIO -
Leonard D Schaeffer,
Director -
Jonathan M Peacock,
CFO -
Gilbert S Omenn,
Director -
J Paul Reason,
Director -
Thomas J.W. Dittrich,
VP, Finance & CAO -
David J Scott,
Sr. VP, Gen. Counsel & Secy. -
A Kelly Michael,
VP Corp Plng & Control & CAO -
Stuart A Tross,
SVP, Human Resources -
Kevin W Sharer,
Chairman of the Bd, CEO & Pres -
Vance D Coffman,
Director -
David W Beier,
SVP Global Govt & Corp Affairs -
Fabrizio Bonanni,
Senior VP, Manufacturing -
Anna Richo,
SVP & CCO -
Jerry D Choate,
Director -
Frederick W Gluck,
Director -
Roger M Perlmutter,
Exec VP Research & Development -
George J Morrow,
Exe VP, Global Commercial Ops -
Brian M Mcnamee,
Sr. V.P. Human Resources -
Richard D Nanula,
Exe VP Fin, Strat & Comm & CFO -
Franklin P Jr Johnson,
Director -
Donald B Rice,
Director -
Dennis M Fenton,
Executive Vice President -
Hassan Dayem,
Sr. V.P. & Chief Info. Officer -
Barry D Schehr,
VP Financial Ops & CAO -
Edward V Fritzky,
Director -
Steven M Odre,
Sr. VP, Gen. Cousel & Secy. -
Timothy O Martin,
V.P., Planning and Control -
Beth C Seidenberg,
Sr VP Development -
Willard H Dere,
Sr. V.P., Global Dev & CMO -
Joseph P Miletich,
Sr VP Rsch & Preclinical Dev -
Patricia C Sueltz,
Director -
Steven Lazarus,
Director -
Derek Miller,
SVP, Human Resources -
Omar Ishrak,
Director -
Rachna Khosla,
SVP, Business Development -
Michael V Drake,
Director -
Matthew C. Busch,
VP, Finance & CAO -
Mary E. Klotman,
Director